| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Edotecarin: A Novel Topoisomerase I Inhibitor
|
Saif, M. Wasif
|
|
2005
|
5 |
1 |
p. 27-36
10 p.
|
artikel
|
| 2 |
Immunologic Therapies for Gastrointestinal Cancers
|
Levy, Benjamin
|
|
2005
|
5 |
1 |
p. 37-49
13 p.
|
artikel
|
| 3 |
Making Sense out of Antisense Thymidylate Synthase
|
Chu, Edward
|
|
2005
|
5 |
1 |
p. 12-
1 p.
|
artikel
|
| 4 |
Recent Results and Ongoing Trials with Panitumumab (ABXEGF), a Fully Human Anti–Epidermal Growth Factor Receptor Antibody, in Metastatic Colorectal Cancer
|
Tyagi, Preeta
|
|
2005
|
5 |
1 |
p. 21-23
3 p.
|
artikel
|
| 5 |
Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer
|
Cartwright, Thomas
|
|
2005
|
5 |
1 |
p. 50-56
7 p.
|
artikel
|
| 6 |
Severe Irinotecan-Induced Toxicities in a Patient with Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphism
|
Mehra, Ranee
|
|
2005
|
5 |
1 |
p. 61-64
4 p.
|
artikel
|
| 7 |
The rTS Signaling Pathway as a Target for Drug Development
|
Dolnick, Bruce J.
|
|
2005
|
5 |
1 |
p. 57-60
4 p.
|
artikel
|
| 8 |
Vatalanib (PTK787/ZK 222584) in Combination with FOLFOX4 Versus FOLFOX4 Alone as First-Line Treatment for Colorectal Cancer: Preliminary Results from the CONFIRM-1 Trial
|
Tyagi, Preeta
|
|
2005
|
5 |
1 |
p. 24-26
3 p.
|
artikel
|
Tijdschrift beschrijving